Crozer-Chester Medical Center closes, marking end of Delaware County's largest hospital system
Crozer-Chester Medical Center closed its doors Friday, marking the end of Delaware County, Pennsylvania's largest health system. Crozer Health served Delco for generations, and its closure has caused sadness and anger in the community.
Crozer-Chester, located in Upland, shut its doors at 8 a.m. Friday. Hallways, patient rooms and operating rooms are now empty inside the hospital, as patients are now trying to figure out where to go to get care.
The hospital's closure marks the end of Crozer Health in Delaware County. Last week, a federal bankruptcy judge authorized Prospect Medical Holdings' plan to close Crozer Health. Four days after the judge's ruling, Prospect closed Taylor Hospital in Ridley Park on April 26. Now, 10 days after the judge's ruling, the California-based company closed Crozer-Chester.
Plans to save Crozer Health failed, leading to about 2,600 layoffs and just two hospitals — Riddle Hospital in Media and Mercy Fitzgerald in Darby — left to serve the county's 585,000 residents. Delaware County's delegation of state lawmakers has asked Pennsylvania Attorney General Dave Sunday to open a criminal investigation into Prospect.
CBS News Philadelphia
Erica Pasquarello, a nurse practitioner at Crozer-Chester, said working for the health system has been part of her family for years.
"I've had family that have been in this system for years," Pasquarello said."My pop-pop was a radiologist in '65, my mom was a nurse at Taylor, she's now a nurse practitioner at Brinton Lake. So it's sad, it's sad."
Pasquarello will have to find a new job now, but her unemployment is not at the top of her mind.
"The patients, I think, if anything, that's the devastating part. Saying goodbye to the last few I have on the schedule today," Pasquarello said. "And I just hope that someone is going to come through and help this community out. Because if anything, they're the ones that are going to suffer the most."
With Crozer Health's closure, there's a lot of uncertainty for patients as they search for new health care services. VMSC Emergency Medical Services, a Montgomery County-based company, has agreed to provide ambulance service for parts of Delaware County, including the City of Chester, Springfield, Marcus Hook and Swarthmore.
Some Crozer-Chester employees are planning to say goodbye in a farewell tailgate Friday afternoon. Also happening today, Keystone First Wellness and Opportunity Center held an event to help former Crozer patients find new primary care physicians and medical specialists.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
2 hours ago
- Forbes
Burnout Or Biology? Metabolic Health Drives Entrepreneur Success
BEVERLY HILLS, CA - OCTOBER 28: Emilia Clarke (Right) and Sharon Waxman, TheWrap's CEO and ... More Editor-in-Chief (Photo byfor TheWrap) The world's most forward-thinking founders aren't just measuring revenue or user acquisition; they're monitoring metabolic performance. Tools like continuous glucose monitors (CGMs), mitochondrial assessments and circadian rhythm trackers are fast becoming C-suite essentials. The reason? Burnout is no longer a productivity tax that needs to be normalized. It's a biological signal that something deeper is off. Within our current volatile entrepreneurial landscape, a new paradigm is emerging, one that treats metabolic health not as a wellness fad but as a strategic performance metric. At its core, this shift reframes bioenergetics as leadership currency: a founder's ability to perform under pressure, think clearly and lead with emotional resilience is directly tied to cellular efficiency. Metabolic health refers to the body's ability to regulate glucose, insulin, lipids, inflammation and energy production effectively. Unlike conventional health goals centered on weight or appearance, metabolic optimization focuses on internal function. Enter: hormonal balance, mitochondrial resilience, metabolic flexibility, or the ability to switch efficiently between fuel sources. This flexibility allows leaders to sustain focus without crashing, reduce their dependency on caffeine or sugar and recover from stress with greater ease. As neuroscience increasingly shows, stable metabolism supports executive function by aligning brain and gut rhythms, both crucial for strategic decision-making. It comes as no surprise, then, that disrupted rhythms from poor sleep, chronic stress and erratic eating silently sabotage performance. What looks like a mindset issue (brain fog, emotional reactivity, impulsivity) is often a mitochondrial issue in disguise. Glucose is the brain's preferred fuel, especially the prefrontal cortex, which governs decision-making, foresight and emotional regulation. Fluctuations in blood sugar can trigger mood volatility and mental fatigue, mimicking burnout. When metabolic dysfunction becomes chronic, cognitive capital deteriorates. Research suggests that workplace interventions targeting metabolic health can reduce perceived stress, prevent burnout and boost self-efficacy. For high-stakes entrepreneurs, this translates into sharper focus, faster recovery and a more grounded, aligned leadership lifestyle. Founders are now embracing data-driven tools to optimize their biological systems. Popular devices and practices include: Executives at Levels Health, InsideTracker and other biohacking-forward VC firms are leading the charge, blending health optimization with high-performance strategy. Some companies are even incorporating mitochondrial health assessments and biological age tests into leadership retreats and C-suite onboarding. Jet lag, pitch decks, red-eye flights and late-night decision sprints take a toll. Entrepreneurial lifestyles often glorify the grind, but the biochemical impact is true to life: elevated cortisol, impaired glucose control and circadian disruption fuel chronic inflammation, eroding resilience from the inside out. A 2025 study found that stress-induced metabolic dysfunction in healthcare professionals mirrors patterns seen in tech executives: high output paired with poor recovery. Over time, this results in mitochondrial fatigue, hormone imbalances and emotional burnout, not because founders are undisciplined but because their internal systems are under siege. The good news? Metabolic health is highly modifiable and functional. Entrepreneurs are turning to science-backed interventions like: However, the most overlooked intervention is also the most essential: sleep. Without circadian balance, even the most sophisticated strategies won't yield results. Deep rest is the bedrock of sustained performance. Note: Always consult your primary care provider before initiating any new health interventions. The most effective leaders integrate biological metrics into their performance strategies. From glucose variability and heart rate variability to mitochondrial health and circadian alignment, internal data is fast becoming as critical as quarterly reports. Metabolically optimized leaders demonstrate improved cognitive function, emotional regulation and decision-making capacity: key traits backed by neuroscience and performance psychology. Emerging organizational models reflect this shift, with VC firms and executive teams investing in biologically intelligent infrastructure: continuous monitoring tools, resilience protocols and recovery-based culture design. Burnout is no longer a vague emotional state but a measurable physiological response driven by chronic inflammation, insulin resistance and cellular fatigue. And treating it goes beyond rest. It requires recalibration at the metabolic level, the epitome of every leader's imperative. The next KPI isn't visible on a spreadsheet. It's encoded in your biology. Optimize it, and you'll gain not just longevity but a strategic edge.
Yahoo
3 hours ago
- Yahoo
Bestselling Author and Food Revolution Network President John Robbins Has Passed Away
A Pioneer Who Changed the Way the World Thinks About Food Leaves a Lasting Legacy SANTA CRUZ, Calif., June 14, 2025--(BUSINESS WIRE)--John Robbins, bestselling author, activist, and co-founder of Food Revolution Network (FRN), has passed away from complications of post-polio syndrome. A trailblazer for ethical, healthy, and sustainable food systems, Robbins' work sparked a worldwide movement that continues to shape policy, science, and public consciousness. His bestselling 1987 book Diet for a New America exposed the health, environmental, and ethical costs of industrialized animal agriculture. Robbins went on to author several more bestsellers, including The Food Revolution and Reclaiming Our Health, reaching millions and inspiring a global shift toward conscious eating. Turning away from a path of inherited wealth as the presumed heir to the Baskin-Robbins empire, Robbins chose to champion a life of integrity. His activism extended beyond books: he served on nonprofit boards, spoke on global stages, and received numerous accolades, including the Rachel Carson Award and the Green America Lifetime Achievement Award. Despite contracting polio at age five, Robbins defied medical expectations to become a marathoner, yogi, and triathlete. Diagnosed in 2019 with Post-Polio Syndrome, he continued to live vibrantly—a testament to the diet and lifestyle he advocated. Robbins' legacy lives on through the million-member Food Revolution Network and the newly formed nonprofit, Food Revolution Alliance (FRA), both dedicated to promoting healthy, ethical, and sustainable food for all. "My father was my mentor, my colleague, and my treasured friend," said Ocean Robbins, FRN CEO. "His love, courage, and wisdom touched countless lives. Now, we carry his torch forward." A family statement added: "John met life's challenges with resilience and with love. Even in the face of pain, he never stopped growing, learning, or seeking to make a difference in the lives of others. His presence and his purpose continue to guide and inspire us every day." To learn more, please visit: To honor his legacy, donations may be made to the Food Revolution Alliance at View source version on Contacts Media Contact: Sierra Kohlruss, Chief Operating OfficerEmail: media@ Website: Sign in to access your portfolio
Yahoo
3 hours ago
- Yahoo
Jasper Therapeutics Reports Positive Data from 180mg Cohort in SPOTLIGHT Study of Briquilimab in Chronic Inducible Urticaria
11 of 12 participants (92%) enrolled in the 180mg cohort achieved a complete response 12 of 12 participants (100%) in the 180mg cohort achieved a clinical response Tryptase levels below the lower limit of quantification observed in 10 of 12 participants (83%) No serious adverse events and no grade 3 or higher adverse events reported in the 180mg cohort Company to host conference call and webinar on Monday, June 16, at 8:00 a.m. EDT REDWOOD CITY, Calif., June 14, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, is presenting data from the 180mg cohort of the Company's SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with CIndU at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress. Briquilimab (subcutaneous) administration resulted in deep disease control at 180mg, with 12 of 12 participants (100%) enrolled in the cohort achieving a clinical response within the 8-week preliminary analysis period. The efficacy observed was rapid and durable, with 8 of 12 participants (66%) achieving clinical response by week 2, and 7 of 12 participants (58%) maintaining clinical response through week 8. Briquilimab continued to be well tolerated in the study, with no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) reported in the 180mg cohort. 'We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,' said Ronald Martell, President and Chief Executive Officer of Jasper. 'In addition to the responses observed, we are pleased that briquilimab continued to be well tolerated in the study. Taken together with the results observed thus far in the BEACON study in CSU, these data demonstrate the ability of briquilimab to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms, along with a potentially differentiated safety profile. On behalf of the entire Jasper team, I'd like to thank both the investigators and the patients who participated in SPOTLIGHT, along with their families and caregivers.' SPOTLIGHT Study Design and Data Summary: The SPOTLIGHT study is a Phase 1b/2a open label clinical trial evaluating a single dose of subcutaneous briquilimab in adult participants with cold urticaria (ColdU) or symptomatic dermographism (SD), the two most prevalent sub types of CIndU, who are refractory to antihistamines. The study enrolled 27 participants across three dose cohorts, 40mg (n=3), 120mg (n=12), and 180mg (n=12). The primary endpoints are safety and tolerability of briquilimab and secondary endpoints are focused on clinical activity and PK/PD, including measurement of serum tryptase. Among the 12 participants enrolled in the 180mg cohort, 3 were diagnosed with ColdU (25%) and 9 with SD (75%). Participants had high disease burden as assessed by provocation threshold testing. In the 180mg cohort, mean baseline TempTest® threshold was 18.7°C (range: 10-26°C) for ColdU participants, and mean baseline FricTest® threshold was 3.7 of 4 (range: 3-4) for SD participants. 12 of 12 participants (100%) enrolled in the 180mg dose cohort achieved a clinical response to provocation testing within the 8-week preliminary analysis period following treatment. 11 of 12 participants (92%) treated in the cohort achieved a complete response (CR) with either their critical temperature threshold improving to at least 4°C for ColdU participants or their FricTest® score improving to 0 for SD participants, and 1 of 12 participants achieved a partial response (PR) as their best response. Complete responses in TempTest® or FricTest® were observed as early as 1 week following dosing in the 180mg cohort, with 8 of 12 participants (66%) achieving CR or PR by week 2. Overall, 22 of 27 participants (81%) enrolled in the study achieved a CR and 26 of 27 participants (96%) achieved a CR or PR. Briquilimab40mg(n=3) Briquilimab120mg(n=12) Briquilimab180mg(n=12) BriquilimabAll doses (n=27) Complete Response, n (%) 1 (33.3%) 10 (83.3%) 11 (91.6%) 22 (81.5%) ColdU, n 0 3 3 6 Symptomatic Dermographism, n 1 7 8 16 Partial Response, n (%) 2 (66.7%) 1 (8.3%) 1 (8.4%) 4 (14.8%) ColdU, n 1 0 0 1 Symptomatic Dermographism, n 1 1 1 3 Complete or Partial Response at any time, n (%) 3 (100%) 11 (91.6%) 12 (100%) 26 (96.3%) At the 8-week timepoint following treatment, 7 of 12 (58%) participants in the 180mg cohort maintained an ongoing clinical response, with 5 participants achieving CR and 2 participants achieving PR. Mean baseline serum tryptase for participants in the 180mg cohort was 5.1 ng/ml (standard deviation: 2.29 ng/ml). Significant reductions in tryptase were observed as early as the week 1 assessment and were correlated with the onset of clinical responses. Tryptase measurements below the lower limit of quantification were observed in 10 of 12 participants (83%) in the 180mg cohort. Briquilimab was well tolerated in the study. No SAEs or AEs ≥ grade 3 were reported in the 180mg cohort. Furthermore, there were no reported AEs related to hair or skin color changes. 2 of 12 participants (17%) enrolled in the 180mg cohort experienced taste change/hypogeusia. Mild, transient drops in neutrophil counts were observed, with 6 of 12 participants (50%) experiencing grade 1 or grade 2 neutrophil count decreases which resolved in a median of 16 days. 5 of the 6 participants who experienced neutrophil count decreases were diagnosed with concurrent viral infections that may have contributed to observed decreases. 'It is exciting to see additional clinical data showing that treatment with briquilimab can lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population,' said Martin Metz, M.D., Professor of Dermatology and Allergy Charité – Universitätsmedizin Berlin. 'Notably, the safety and tolerability results observed in both the SPOTLIGHT and BEACON studies thus far show that the adverse events possibly caused by briquilimab are mostly low frequency, low grade, and resolve quickly. Patients with CIndU currently have very few treatment options, and I look forward to continuing to support the development of novel therapeutics to treat this debilitating disease.' Conference Call / Webinar Jasper will host a conference call and webinar on Monday, June 16, 2025, at 8:00 a.m. EDT. A live question and answer session with management will follow the formal presentations. A link to the webinar, including presentation slides, can be found here. To access the live conference call via phone, dial 1-844-826-3033 from the US or 1-412-317-5185 from outside the US, or click here. The conference ID is 10200147, and the conference call passcode is 6392607. The presentation slides and a link to the live and archived webinar will also be available on the Events & News – Events page of Jasper's Investor Relations website. About Jasper Jasper is a clinical-stage biotechnology company focused on developing briquilimab as a therapeutic for chronic mast cell diseases. Briquilimab is a targeted aglycosylated monoclonal antibody that blocks stem cell factor from binding to the cell-surface receptor KIT, thereby inhibiting signaling through the receptor. This inhibition disrupts the critical survival signal, leading to the depletion of the mast cells via apoptosis which removes the underlying source of the inflammatory response in mast cell driven diseases such as chronic urticaria and asthma. Jasper is currently conducting clinical studies of briquilimab as a treatment in patients with CSU, CIndU or asthma. Briquilimab has a demonstrated efficacy and safety profile in patients and healthy volunteers, with positive clinical outcomes in CSU and CIndU. For more information, please visit us at Forward-Looking Statements Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as 'believe,' 'may,' 'will,' 'estimate,' 'continue,' 'anticipate,' 'intend,' 'expect,' 'should,' 'would,' 'plan,' 'predict,' 'potential,' 'seem,' 'seek,' 'future,' 'outlook' and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding briquilimab's potential, including with respect to its potential in mast cell driven diseases such as CSU, CIndU, and asthma; briquilimab's ability to support optimal biologic dosing by rapidly delivering robust and durable control of urticaria symptoms along with a potentially differentiated safety profile; and the potential for treatment with briquilimab to lead to deep clinical benefit shortly after administration in a difficult-to-treat antihistamine refractory CIndU patient population. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Jasper and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Many actual events and circumstances are beyond the control of Jasper. These forward-looking statements are subject to a number of risks and uncertainties, including general economic, political and business conditions; the risk that the potential product candidates that Jasper develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; the risk that clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release; the risk that prior test, study and trial results may not be replicated in continuing or future studies and trials; the risk that Jasper will be unable to successfully market or gain market acceptance of its product candidates; the risk that prior study results may not be replicated; the risk that Jasper's product candidates may not be beneficial to patients or successfully commercialized; patients' willingness to try new therapies and the willingness of physicians to prescribe these therapies; the effects of competition on Jasper's business; the risk that third parties on which Jasper depends for laboratory, clinical development, manufacturing and other critical services will fail to perform satisfactorily; the risk that Jasper's business, operations, clinical development plans and timelines, and supply chain could be adversely affected by the effects of health epidemics; the risk that Jasper will be unable to obtain and maintain sufficient intellectual property protection for its investigational products or will infringe the intellectual property protection of others; and other risks and uncertainties indicated from time to time in Jasper's filings with the SEC, including its Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q. If any of these risks materialize or Jasper's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While Jasper may elect to update these forward-looking statements at some point in the future, Jasper specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Jasper's assessments of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements. Contacts: Alex Gray (investors) Jasper Therapeutics 650-549-1454 agray@ Joyce Allaire (investors) LifeSci Advisors 617-435-6602 jallaire@ Lauren Walker (media) Real Chemistry 646-564-2156 lbarbiero@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
